Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.

ABSTRACT:

Purpose/objectives

Radiation therapy (RT) is the principal modality in the treatment of patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase inhibitors in the central nervous system, it is uncertain whether upfront brain RT is necessary for patients with EGFR-mutant lung adenocarcinoma with BM.

Methods and materials

Patients with EGFR-mutant lung adenocarcinoma and newly diagnosed BM were identified.

Results

222 patients were identified. Exclusion criteria included prior erlotinib use, presence of a de novo erlotinib resistance mutation, or incomplete data. Of the remaining 110 patients, 63 were treated with erlotinib, 32 with whole brain RT (WBRT), and 15 with stereotactic radiosurgery (SRS). The median overall survival (OS) for th

SUBMITTER: Gerber NK 

PROVIDER: S-EPMC5691362 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature